Article

Diagnostic profile measures stone formation risk factors

Mission Pharmacal offers the StoneRisk Diagnostic Profile, which measures10 urine risk factors for stone formation. It offers a urine collectionand preservation system and is recommended for initial and recurrent stoneformers who test positive for a urinary tract infection, according to thecompany. Test results are shown on a computer-generated graphic display.

Related Videos
1 expert in this video
1 expert is featured in this series.
1 expert is featured in this series.
Anna Myers, CNP, answers a question during a Zoom video interview
Related Content
Benign Prostatic Hyperlasia | Image Credit: © Judith - stock.adobe.com
April 28th 2025

Investigational ProVee System impresses in phase 3 trial in BPH

Benjamin P. Saylor
No device- or procedure-related serious AEs were observed through 12 months across the entire study population
Pearls & Perspectives: Martin Kathrins, MD, on MED3000 and learning from failed trials
April 28th 2025

Pearls & Perspectives: Martin Kathrins, MD, on MED3000 and learning from failed trials

Amy M. Pearlman, MD Martin Kathrins, MD
Kathrins discusses the intricacies of leading a clinical trial and why "negative" trials are important to informing care strategies.
Kidney stones | Image Credit: © airborne77 - stock.adobe.com
April 28th 2025

CVAC 2.0 demonstrates efficacy for clearing stones less than 2 cm

Benjamin P. Saylor
The investigators reported a median stone clearance of 96.44%.
Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause
April 28th 2025

Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

Melissa Kaufman, MD, PhD, FACS
In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
Sam S. Chang, MD, MBA
April 28th 2025

Nogapendekin alfa inbakicept shows high CR, avoidance of cystectomy in NMIBC

Benjamin P. Saylor
In cohort A, the cystectomy-free rate at 36 months was 84%.
Stephen J. Freedland, MD
April 28th 2025

Most men in EMBARK trial recover T levels following treatment suspension

Benjamin P. Saylor
More than 80% of patients in both groups had a full recovery of testosterone.
© 2025 MJH Life Sciences

All rights reserved.